Duration of Therapy and Dosing Strategies in RCC

Opinion
Video

An expert on non–clear cell renal cell carcinoma provides clinical insights on TKI dosing strategies and duration of therapy implications for IO-TKI combinations.

Video content above is prompted by the following question(s):

  • In your experience, what is the optimal duration of treatment with lenvatinib in patients with advanced renal clear cell carcinoma?
    • How do you monitor patients and make decisions around continuing or discontinuing treatment in clinical practice?
    • When do you consider switching therapies versus dose reductions to maintain treatment duration?


Related Videos
Martin H. Voss, MD, an expert on kidney cancer
2 KOLs are featured in this program.
2 KOLs are featured in this program.
Martin H. Voss, MD, an expert on kidney cancer
Martin H. Voss, MD, an expert on kidney cancer
2 KOLs are featured in this program.
2 KOLs are featured in this program.
Martin H. Voss, MD, an expert on kidney cancer
Guillermo Garcia-Manero, MD, an expert on MDS
Related Content